[go: up one dir, main page]

WO2007069070A3 - Aseptically filled multidose injectable dosage forms of granisetron - Google Patents

Aseptically filled multidose injectable dosage forms of granisetron Download PDF

Info

Publication number
WO2007069070A3
WO2007069070A3 PCT/IB2006/003661 IB2006003661W WO2007069070A3 WO 2007069070 A3 WO2007069070 A3 WO 2007069070A3 IB 2006003661 W IB2006003661 W IB 2006003661W WO 2007069070 A3 WO2007069070 A3 WO 2007069070A3
Authority
WO
WIPO (PCT)
Prior art keywords
granisetron
multidose
dosage forms
aseptically filled
injectable dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/003661
Other languages
French (fr)
Other versions
WO2007069070A2 (en
Inventor
Chandrashekar Shahaji Kadam
Bhavesh Vallabhbhai Patel
Girish Kumar Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of WO2007069070A2 publication Critical patent/WO2007069070A2/en
Anticipated expiration legal-status Critical
Publication of WO2007069070A3 publication Critical patent/WO2007069070A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to aseptically filled multidose injectable dosage forms of granisetron or salts thereof, and processes for their preparation.
PCT/IB2006/003661 2005-12-16 2006-12-18 Aseptically filled multidose injectable dosage forms of granisetron Ceased WO2007069070A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1587/MUM/05 2005-12-16
IN1587MU2005 2005-12-16

Publications (2)

Publication Number Publication Date
WO2007069070A2 WO2007069070A2 (en) 2007-06-21
WO2007069070A3 true WO2007069070A3 (en) 2009-04-16

Family

ID=38163289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003661 Ceased WO2007069070A2 (en) 2005-12-16 2006-12-18 Aseptically filled multidose injectable dosage forms of granisetron

Country Status (1)

Country Link
WO (1) WO2007069070A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372057B (en) 2008-12-11 2012-09-11 Dev Center Biotechnology Sustained release implant for granisetron

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211982A1 (en) * 2002-12-20 2006-09-21 Steven Prestrelski Intracutaneous injection
US20070015808A1 (en) * 2005-07-13 2007-01-18 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3. 1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211982A1 (en) * 2002-12-20 2006-09-21 Steven Prestrelski Intracutaneous injection
US20070015808A1 (en) * 2005-07-13 2007-01-18 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3. 1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride

Also Published As

Publication number Publication date
WO2007069070A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2007002635A3 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2008115281A3 (en) Compounds for treating viral infections
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
MX2010005889A (en) Novel thiophene derivatives.
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2007086001A3 (en) Novel pyridine derivatives
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
MX2010004576A (en) Novel pyrimidine derivatives.
WO2009129246A3 (en) Compositions and methods for preparing and using same
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
PL2364983T3 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
HK1217294A1 (en) 4'-fluor0-2'-methyl substituted nucleoside derivatives
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
EA201000039A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING SOLIFENACIN OR ITS PHARMACEUTICALLY ADAPTABLE SALT
WO2010019511A3 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2008051539A3 (en) Processes for preparing palonosetron salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1225/MUMNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06831743

Country of ref document: EP

Kind code of ref document: A2